# A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

> **NCT07416604** · PHASE3 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 360 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **COMBINATION_PRODUCT:** NXT007
- **DRUG:** Emicizumab

## Key facts

- **NCT ID:** NCT07416604
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-27
- **Primary completion:** 2028-02-29
- **Final completion:** 2032-01-29
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07416604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07416604, "A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07416604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*